Found on Fox Health. A typo in the headline raises all kinds of interesting images.
Derma Sciences Foot-Wound Rug Shows Promise
Published May 27, 2011
BANGALORE – Derma Sciences Inc said foot ulcers in 85 percent of diabetic patients healed completely after being treated with its experimental drug at the end of a 24-week trial, improving its chances of licensing the drug to potential partners.
Shares of the company, which specializes in wound-care products, jumped 25 percent to a more than three-month high of $11.65 in afternoon trade on Wednesday on Nasdaq.
The data will help the company in outlicensing ex-U.S. rights of the drug, codenamed DSC127, to a potential partner, Chief Executive Edward Quilty said in an interview.
Rodman & Renshaw analyst Michael Higgins said, "I think, the 24-week data increases Derma's negotiating power with potential collaborators."
Higgins, who has a "market outperform" rating on the stock, said he was most impressed by the drug's ability to heal wounds 13.5 week sooner than the placebo.